

# The Walter P. Scheffe Continuing Pharmaceutical Education Series

**October 28-29, 2023**

The University of Oklahoma  
College of Pharmacy  
1110 N. Stonewall Ave., Room 101  
Oklahoma City, Oklahoma 73117

Hosted by:



**COLLEGE OF PHARMACY**  
*The UNIVERSITY of OKLAHOMA HEALTH SCIENCES CENTER*



The University of Oklahoma College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

## Program Registration

Name	Pharmacy Setting
NABP e-Profile ID #	Month/Day of Birth (MMDD)
Home Address	City, State, Zip
Phone	Email

### Registration Costs

#### Saturday

\$150.00 Pre-Registration

\$165.00 On-Site Registration

#### Sunday

\$150.00 Pre-Registration

\$165.00 On-Site Registration

*The registration fee includes all activity materials, continental breakfast, lunch and refreshments. A link to the program documents will be provided to registered participants. It is encouraged to download/print materials in advance. Wi-Fi will be available on-site.*

I will download/print my own materials.

I would like my materials printed for me.

### Payment Method

Credit Card

Check

If check is enclosed:

Amount \$ \_\_\_\_\_ Check # \_\_\_\_\_

You can submit payment via credit card online through our secure website: <https://pharmacy.ouhsc.edu/marketplace> --> Alumni Store.

To register, please use the link above or mail/fax a completed registration form and payment to:

OU College of Pharmacy – Office of Alumni Affairs  
P.O. Box 26901, CPB 104D, Oklahoma City, OK 73126  
Phone: (405) 271-6194 Fax: (405) 271-3830

## October 28, 2023

---

8 contact hours (0.8 CEUs) total

7:30-7:55am **Registration & Breakfast**

7:55-8:00am **Introduction**

8:00-10:00am **Improving Quality of Care and Outcomes: Applications of Pharmacoeconomics and Value-Based Frameworks\* (K)**

ACPE# 0053-0000-23-024-L05-P 2 contact hours (0.2 CEUs)  
*Grant Skrepnek, Ph.D., M.Sc., R.Ph.*

10:00-10:15am **Break**

10:15-12:15pm **Managing Major Geriatric Syndromes - Fact, Fiction, Updates and Clinical Pearls\* (A)**

ACPE# 0053-0000-23-025-L01-P 2 contact hours (0.2 CEUs)  
*Keith Swanson, Pharm.D.*

12:15-12:45pm **Lunch**

12:45-1:45pm **Breaking Bad Cholesterol: The Latest Dyslipidemia Management Strategies\* (A)**

ACPE# 0053-0000-23-026-L01-P 1 contact hour (0.1 CEU)  
*Jordan Fuller, Pharm.D., M.B.A., BCPS, BCCCP*

1:45-2:45pm **USP 795 and 797 Chapter Updates\* (K)**

ACPE# 0053-0000-23-027-L07-P 1 contact hour (0.1 CEU)  
*Wendy Galbraith, Pharm.D., FAPhA, BCNP*

2:45-3:00pm **Break**

3:00-5:00pm **The Ins and Outs of Ups and Downs: Antidepressant, Neuroleptic, and Lithium Overdoses\* (A)**

ACPE# 0053-0000-23-028-L01-P 2 contact hours (0.2 CEUs)  
*Kristie Edelen, Pharm.D., D.A.B.A.T.*

5:00-5:05pm **Closing Remarks & Evaluation**

## October 29, 2023

---

7 contact hours (0.7 CEUs) total

7:30-7:55am **Registration & Breakfast**

7:55-8:00am **Introduction**

8:00-9:30am **Incretin-Based Therapies: The Past, Present, and Future of Weight Loss Drugs\* (A)**

ACPE# 0053-0000-23-029-L01-P 1.5 contact hours (0.15 CEUs)  
*Jeremy Johnson, Pharm.D., BCACP, CDCEs, BC-ADM*

9:30-9:45am **Break**

9:45-10:45am **The Sweet Accessibility of Continuous Glucose Monitors\* (K)**

ACPE# 0053-0000-23-030-L01-P 1 contact hour (0.1 CEU)  
*Julia McElyea, Pharm.D., BCACP*

10:45-11:45am **It Takes Two to Tango: Dual Inhaled Bronchodilators for Chronic Obstructive Pulmonary Disease\* (A)**

ACPE# 0053-0000-23-031-L01-P 1 contact hour (0.1 CEU)  
*Paul Boylan, Pharm.D., BCPS*

11:45-12:15pm **Lunch**

12:15-1:45pm **Oklahoma State Board of Pharmacy Rule Update\* (K)**

ACPE# 0053-0000-23-032-L03-P 1.5 contact hours (0.15 CEUs)  
*Marjan Fardadfar, Pharm.D., D.Ph., BCGP*

1:45-2:00pm **Break**

2:00-4:00pm **This is The Way: Empiric Treatment Updates of Infectious Diseases\* (A)**

ACPE# 0053-0000-23-033-L01-P 2 contact hours (0.2 CEUs)  
*Kelly Murray, Pharm.D., BCACP*

4:00-4:05pm **Closing Remarks & Evaluation**

## Awarding Credit

---

This seminar offers a total of 15 contact hours (1.5 CEUs) of ACPE-accredited continuing pharmacy education credit accepted by the Oklahoma Board of Pharmacy and most other states. Credit will be earned based on the participation in individually accredited activities. Full attendance and participation are required before obtaining CPE credit. Partial credit will not be awarded. Any individual who is over 10 minutes late or leaves early will not be granted credit. The University of Oklahoma College of Pharmacy, as an ACPE-accredited provider, is required to report all credit through CPE Monitor. Credit will be available online to participants within four weeks. A notification email will be sent to participants when credit is uploaded. The initial release date is 10/28/23. For successful completion and subsequent awarding of credit, the attendance verification procedure will require each participant to: sign in on the morning and afternoon sign-in sheet, provide NABP e-Profile ID # and month and day of birth, participate in the learning assessments, return nametag at the end of the final session attended, and complete the online program evaluation.

## Registration & Contact Info

---

Pre-registration is suggested to allow OUCOP to provide the appropriate faculty and materials necessary to meet the program objectives. Early registration is \$150/day and will be accepted until 10/27/23. OUCOP reserves the right to limit registrations or cancel courses. There are no refunds. For questions, concerns, or grievances, please contact the OUCOP Continuing Education Administrator at Cassidy-Roberts@ouhsc.edu or (405) 271-6194.

---

\*Denotes sessions of Continuing Education credit  
(K)=Knowledge-based (A)=Application-based

Continuing education activities are structured to meet knowledge- and/or application-based education needs. A knowledge-based activity is for participants to acquire factual knowledge. An application-based activity is for participants to apply the information learned in the allotted timeframe. Information in all CE activities is based on evidence as accepted in the literature by the health care professions.

# Target Audience & Learning Objectives

This continuing pharmacy education program is intended for pharmacists in any practice setting. At the completion of this activity, the participant will be able to:

## **ACPE # 0053-0000-23-024-L05-P (K)**

Summarize general principals of value, cost-effectiveness analyses, and value-based frameworks  
Define and quantify the incidence, prevalence, and impact of medical errors, medication errors, drug-related problems, adverse drug events, and adverse drug reactions

## **ACPE # 0053-0000-23-025-L01-P (A)**

Compare the pharmacologic activity and potential adverse effects of medications used to manage dementia  
Predict the potential benefits and risks associated with the use of medications commonly used to treat urinary incontinence  
Describe the known benefit of medications and nutritional supplements used to reduce the risk of recurrent UTIs  
Examine the potential benefits and risks associated with therapies for managing the behavioral and psychiatric symptoms of dementia  
Summarize the potential benefits and risks associated with medications used to manage weight loss in older individuals

## **ACPE # 0053-0000-23-026-L01-P (A)**

Interpret treatment recommendations included in the 2018 ACC-AHA, 2019 ESC/EAS, and 2020 AACE/ACE hypercholesterolemia guidelines  
Explain the role of nonstatin therapies for LDL-cholesterol management  
Apply guidelines for the management of patients with hypercholesterolemia

## **ACPE # 0053-0000-23-027-L07-P (K)**

Report the major changes in USP compounding chapters  
Classify a sterile preparation given the environmental engineering controls  
Identify the appropriate beyond-use date for acquired data

## **ACPE # 0053-0000-23-028-L01-P (A)**

Describe the mechanisms of toxicity and clinical effects of antidepressant and neuroleptic medications  
Develop a treatment strategy for a patient suffering from antidepressant and neuroleptic overdose  
Choose effective treatment plans for serotonin toxicity and neuroleptic malignant syndrome

## **ACPE # 0053-0000-23-029-L01-P (A)**

Interpret findings from select trials regarding incretin analogues and weight loss  
Identify which incretin analogue products are approved for weight loss  
Apply evidence of weight loss with incretin analogues to patient case scenarios

## **ACPE # 0053-0000-23-030-L01-P (K)**

Describe the recent expansion of continuous glucose monitoring (CGM) coverage  
Recognize the benefits of CGM use compared to traditional glucose monitoring  
State the differences of personal CGM devices on the market  
Recall recommendations pertaining to the procurement, usage, and interpretation of CGMs

## **ACPE # 0053-0000-23-031-L01-P (A)**

Report updates to the Global Initiative for Obstructive Lung Disease (GOLD) 2023 Report  
Explain the pharmacology, medicinal chemistry, and pharmacokinetic properties of long-acting beta agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)  
Choose long-acting bronchodilators to treat GOLD Categories B and E

## **ACPE # 0053-0000-23-032-L03-P (K)**

Report recent changes in Oklahoma pharmacy laws and rules  
Explain how laws and rules apply to pharmacy practices in Oklahoma

## **ACPE # 0053-0000-23-033-L01-P (A)**

List appropriate first- and second-line options for urinary tract infections  
Choose empiric treatment options for patients diagnosed with community acquired pneumonia based on past medical history  
Select options for acute bacterial skin and skin structure infections in pregnant or breastfeeding patients  
State the current antibiotics and dosages for treatment of gonorrhea  
Analyze literature on anaerobic coverage with metronidazole in pelvic inflammatory disease

# Faculty

## **Paul Boylan, Pharm.D., BCPS**

Assistant Professor  
University of Oklahoma College of Pharmacy | OKC

## **Kristie Edelen, Pharm.D., D.A.B.A.T.**

Managing Director  
Oklahoma Poison Center | OKC

## **Marjan Fardadfar, Pharm.D., D.Ph., BCGP**

Compliance Officer  
Oklahoma State Board of Pharmacy | OKC

## **Jordan Fuller, Pharm.D., M.B.A., BCPS, BCCCP**

Assistant Professor  
University of Oklahoma College of Pharmacy | OKC

## **Wendy Galbraith, Pharm.D., FAPhA, BCNP**

Clinical Associate Professor  
University of Oklahoma College of Pharmacy | OKC

## **Jeremy Johnson, Pharm.D., BCACP, CDCES, BC-ADM**

Associate Professor  
SWOSU College of Pharmacy | Tulsa

## **Julia McElyea, Pharm.D., BCACP**

Clinical Assistant Professor  
University of Oklahoma College of Pharmacy | OKC

## **Kelly Murray, Pharm.D., BCACP**

Clinical Associate Professor of Clinical Pharmacy  
OSU Center for Health Sciences | Tulsa

## **Grant Skrepnek, Ph.D., M.Sc., R.Ph.**

Professor  
University of Oklahoma College of Pharmacy | OKC

## **Keith Swanson, Pharm.D.**

Associate Professor  
University of Oklahoma College of Pharmacy | OKC

The University of Oklahoma College of Pharmacy has reviewed this activity's faculty and planner disclosures and mitigated all relevant financial relationships, if applicable. Disclosure and mitigation information will be provided to registrants before the activity. No commercial support was received for this program.

The University of Oklahoma is an equal opportunity institution. Accommodations on the basis of disability are available by contacting Cassidy-Roberts@ouhsc.edu. We are committed to protecting the privacy of our learners. Your personal information will not be shared with anyone outside of the Office of Continuing Education unless you consented to having your name and practice site shared with vendor representatives, if applicable. In that case, no contact details or any other information will be given out. Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of the University of Oklahoma or is licensed or has been granted permission for use by the copyright owner. No materials may be reproduced or transmitted without written permission. All rights reserved. To access the entirety of these policies, visit <https://ou.edu/marcomm/web-policies/termsfuse> and <https://ou.edu/eoo/about/policies-procedures>.